Literatur
- 1
Büchner T, Hiddemann W. et al .
Double induction containing either two courses or one course of high-dose cytarabine
plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation
or by prolonged maintenance for acute myeloid leukemia.
J Clin Oncol.
2006;
24
2480-2489
- 2
Cheson B D. et al .
Revised Recommendations of the International Working Group for Diagnosis, Standardization
of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic
Trials in Acute Myeloid Leukemia.
J Clin Oncol.
2003;
21
4642-4649
- 3
Estey E, Pierce S.
Routine Bone Marrow Exam During First Remission of Acute Myeloid Leukemia.
Blood.
1996;
87
3899-3902
- 4
Giles F. et al .
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent,
combined with cytarabine in patients with refractory leukemia.
Clin Cancer Res.
2005;
11
7817-7824
- 5
Gore S D, Haferlach T, Schoch C. Combination therapy with DNA methyltransferase inhibitors
et al. .
Morphologic dysplasia in hematologic malignancies (Review).
Nat Clin Pract Oncol.
2005;
(Suppl 1)
2
S30-35
- 6
Haferlach T, Schoch C. et al .
Morphologic Dysplasia in De Novo Acute Myeloid Leukemiade novo acute myeloid leukemia
(AML) is related to unfavorable cytogenetics but has no independent prognostic relevance
under the conditions of intensive induction therapy.
J Clin Oncol.
2003;
21
256-265
- 7
Haferlach T, Kern W, Schnittger S, Schoch C.
Modern diagnostics in acute leukemias.
Crit Rev Oncol Hematol.
2005;
56
223-234
- 8
Hiddemann W, Spiekermann K, Buske C. et al .
Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
Crit Rev Oncol Hematol.
2005;
56
235-245
- 9 Kern W, Behre G, von Schilling C. et al .Akute Myeloische Leukämie beim Erwachsenen. 2.
Aufl W. Zuckschwerdt, München In: Leukämien, myelodysplastische und myeloproliferative
Syndrome. Manual des Tumorzentrums München 2003
- 10 Kompetenznetz „Akute und chronische Leukämien” Aktive Studien: Akute myeloische
Leukämie;. www.kompetenznetz-leukaemie.de
- 11
Marcucci G, Mrozek K, Bloomfield C D.
Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia
and normal cytogenetics.
Curr Opin Hematol.
2005;
12
68-75
- 12
Mrozek K, Heerema N A, Bloomfield C D.
Cytogenetics in acute leukemia.
Blood Rev.
2004;
18
115-136
- 13
Schlenk R F. et al .
Phase III study of all-trans retinoic acid in previously untreated patients 61 years
or older with acute myeloid leukemia.
Leukemia.
2004;
18
1798-1803
- 14
Schmid C, Schleuning M, Schwerdtfeger R. et al .
Long term survival in refractory acute myeloid leukemia after sequential treatment
with chemotherapy and reduced intensity conditioning for allogeneic stem cell transplantation.
Blood.
2006;
108
1092-1099
- 15
Schoch C. et al .
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological
entity characterized by genomic imbalances and a specific gene expression profile.
Genes, Chromosomes and Cancer.
2005;
43
227-238
- 16
Schoch C. et al .
The influence of age on prognosis of de novo acute myeloid leukemia differs according
to cytogenetic subgroups.
Haematologica.
2004;
89
1082-1090
- 17
Sievers E, Larson R, Stadtmauer E. et al .
Efficacy and safety of gemtuzumab ozogamacin in patients with CD 33 - positive acute
myeloid leukemia in first relapse.
J Clin Oncol.
2001;
19
3244-3254
- 18
Tournaye H, Goossens E, Verheyen G. et al .
Preserving the reproductive potential of men and boys with cancer: current concepts
and future prospects.
Hum Reprod Update.
2004;
10
525-532
Priv.-Doz. Dr. Christian Buske
Medizinische Klinik III, Klinikum Großhadern der Universität München
Marchioninistraße 15
81377 München
Phone: 089/7099402
Fax: 089/7099400
Email: buske@gsf.de
